logo
10 everyday foods banned in other countries you might still be eating

10 everyday foods banned in other countries you might still be eating

Time of India4 days ago
Some foods that seem totally normal in your local store are actually banned abroad due to serious health and safety concerns. While these items are widely available in many countries, others have outlawed them because of links to cancer, heart disease, allergies, or toxic contamination.
From brightly coloured snacks filled with artificial dyes to chemical-laced sodas and hormone-injected meat, these so-called everyday foods might be putting your health at risk without you realising it. This list breaks down the most controversial everyday foods banned in other countries and why experts recommend reading labels carefully and making more informed food choices.
10 everyday foods banned in other countries
Potassium bromate in bread
Used to make dough rise faster,
potassium bromate
is a common bread additive in India and the US.
But it's considered a potential carcinogen. That's why countries like the UK, Canada, Brazil, and the EU have banned it in all bakery products due to long-term cancer risk.
Farm-raised salmon
Farm-raised salmon are often fed antibiotics and synthetic colour to appear pink. Studies have linked them to high levels of PCBs and dioxins. That's why Australia and New Zealand restrict this type of salmon, favouring wild-caught versions that are less contaminated and more nutritionally beneficial.
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
No annual fees for life
UnionBank Credit Card
Apply Now
Undo
Kinder Joy and Kinder Surprise
The toy-filled
Kinder Surprise
eggs are banned in the United States due to choking hazards, as food products cannot legally contain non-edible parts inside. While Kinder Joy is allowed in some areas due to its split packaging, traditional Kinder Surprise remains illegal in the U.S.
Instant noodles with MSG
Popular brands of instant noodles often contain MSG and TBHQ preservatives, which have been linked to nausea, headaches, and potential neurological issues in sensitive people.
While not globally banned, several European countries have imposed restrictions or require explicit labelling due to health concerns.
Artificial food dyes
Bright-coloured candies and snacks often use
food dyes
like Red 40 and Yellow 5, which are linked to hyperactivity in children and allergic reactions. Many of these dyes are banned or restricted in the EU and UK, while still widely used in other countries.
Ractopamine pork
Ractopamine, a drug used to increase lean meat in pigs, is banned in the EU, China, and Russia.
It can cause heart palpitations and muscle tremors in humans if consumed in excess. Over 160 countries prohibit pork treated with ractopamine, but it's still common in the U.S.
Fugu fish
Also known as pufferfish, fugu is banned in the EU due to its deadly tetrodotoxin content. Even trained chefs risk serving it improperly. One wrong slice can result in death within hours. Despite the danger, it remains a prized delicacy in Japan under strict regulation.
Mountain Dew
Some versions of Mountain Dew and citrus sodas use brominated vegetable oil (BVO) to keep flavours mixed. But BVO is also a flame retardant and can build up in fat tissue. That's why Japan and the European Union have banned it in all food products.
Genetically modified foods (GMOs)
Many processed foods contain GMOs—corn, soy, or canola genetically altered to resist pests or herbicides. While considered safe by some regulators, countries like France, Germany, and Russia ban or heavily restrict GMOs due to long-term environmental and health concerns, especially regarding biodiversity.
Raw milk
Raw milk, or
unpasteurised milk
, can contain bacteria like E. coli and Salmonella. While fans claim it has better nutrients, health agencies warn it can be dangerous—especially for kids and pregnant women. That's why countries like Canada, Australia, and parts of the U.S. have banned its retail sale.
Also read|
How a bowl of salt in fridge can stop smell and spoilage in monsoon
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Woman, pregnant with twins, survives 18-hour heart surgery
Woman, pregnant with twins, survives 18-hour heart surgery

Time of India

timean hour ago

  • Time of India

Woman, pregnant with twins, survives 18-hour heart surgery

Mumbai: A 31-year-old woman, eight months pregnant with twins, was rushed to KEM Hospital for intense chest pain radiating down her spine, and breathlessness. Doctors found a tear in the main blood vessel that carries blood from the heart to the rest of the body. But delays in diagnosis and treatment cost nearly a day, and fearing the loss of all three lives, the family moved her to a private hospital. The mother, Tejaswini Hire, and her two preterm daughters remained at Jaslok Hospital for a month. The total expenses touched around Rs 30 lakh, covering an emergency caesarean, an open-heart surgery, and a month-long admission for all three. The twins turned two months old on Sunday. "At KEM, I was told the costs could be Rs 4 lakh, but the risks seemed too high and we had lost trust," said Nishant Hire, the twins' father. The family lives in Ramabai Ambedkar Nagar in Ghatkopar. "We had to borrow from friends and family, all our savings are exhausted, but at least all three are alive and safe," Hire said. You Can Also Check: Mumbai AQI | Weather in Mumbai | Bank Holidays in Mumbai | Public Holidays in Mumbai A doctor from KEM Hospital said, "They took discharge against medical advice. It was a high-risk case with low survival chances, but we were prepared to operate. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like We Have No Words For Dog The Bounty Hunter's Transformation Cash Roadster Undo In the end, it was the patient's choice." Cardiothoracic surgeon Dr Hemant Pathare, who performed the surgery, explained that in medical terms this was a case of an aortic dissection caused by a genetic disorder called Marfan syndrome. The syndrome can lead to serious heart problems. "The tear had extended to her coronary artery, and the aortic valve was leaking significantly. This caused severe fluid congestion in her lungs, and she had to be put on ventilator. Eventually, there were more complications impacting almost her entire body," he said. The open-heart surgery lasted 18 hours. By the time Tejaswini reached Jaslok, doctors were unable to detect the heartbeat of one of the babies, prompting an emergency C-section. "Marfan syndrome is risky even outside pregnancy, but during pregnancy, the risk to the mother's life is far more. The most dangerous part is that cardiac complications can strike at any time from the first day to just after delivery," said Dr Danny Laliwala, the gynaecologist who performed the delivery. Hire said Tejaswini is still recovering, while the twins are healthy. "She will have to be on lifelong blood thinners. This is likely the first such survival case in the world, given that maternal mortality in such situations can be as high as 50%, and infant mortality even higher," said Dr Pathare.

No More Tears: Needle-Free Injections Arrive For City Kids
No More Tears: Needle-Free Injections Arrive For City Kids

Time of India

timean hour ago

  • Time of India

No More Tears: Needle-Free Injections Arrive For City Kids

1 2 Nagpur: Fear of injections — especially among young children — is a common scene in clinics and hospitals. Even parents often dread the moment when their child has to be held tightly for a painful jab. But that fear might soon become a thing of the past, thanks to a new needle-less injection technique now introduced in Nagpur. On July 26, a major step forward in child-friendly healthcare was demonstrated in the city. Senior paediatrician and medical superintendent of Government Medical College and Hospital (GMCH), Nagpur, Dr Avinash Gawande show the new needle-free injection system, which has already started being used for routine vaccinations in children. "This is a revolution in medical practice, especially for paediatric immunisation," said Dr Gawande. "The technique eliminates the pain, trauma, and fear associated with traditional injections." The needle-less injection device looks somewhat like a small hand-held gun. It works by pushing medicine into the skin using a high-pressure stream of air, eliminating the need for a needle. This method is not only painless but also avoids tissue damage and post-injection swelling caused by traditional syringes. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Is this legal? Access all TV channels without a subscription! Techno Mag Learn More Undo The technology has been in India for just 6 to 8 months but has already reached Nagpur. Currently, about 90% of the injections used in the standard immunisation schedule for children can be safely given using this method. Besides reducing fear, the needle-free system also brings added safety benefits. Since no sharp needles are used, healthcare workers are protected from accidental pricks, and there is minimal risk of spreading infections like HIV or Hepatitis B. According to Dr Gawande, this simple device could dramatically improve vaccination coverage and cooperation, especially in children, who often resist traditional injections. The method is currently being used for people aged 6 months and above. Trials are underway for even younger infants (6 weeks to 6 months), and positive results are expected soon. While slightly more expensive — costing Rs200 to Rs300 more than regular injections — the prices are expected to drop as the technology becomes more widespread. Needle-Free Injection: At A Glance * No needle, no pain – Uses air pressure to deliver the medicine through the skin * No swelling or tissue injury – Reduces post-injection discomfort * Safe for healthcare workers – No risk of accidental needle pricks * Child-friendly – Reduces fear and improves vaccination experience * Effective like traditional injections – Suitable for both intramuscular and intradermal delivery * Currently for liquid medicines – Works best for vaccines and other fluid-based drugs

Cheaper cancer care therapy earns big bucks for pharma company
Cheaper cancer care therapy earns big bucks for pharma company

Economic Times

time3 hours ago

  • Economic Times

Cheaper cancer care therapy earns big bucks for pharma company

India's cell and gene therapy pioneer ImmunoAct has turned profitable in its first full year of operations, a rare feat in the country's emerging startup landscape where research-based pharma enterprises encounter serious scale and cash flow challenges. ImmunoACT, in which Hyderabad-based drugmaker Laurus Labs has roughly 34% equity stake, saw revenues of ₹62 crore with a profit before tax of ₹12 crore in FY25, according to sources. The year before, ImmunoAct had revenues of ₹11 crore. Founded by immunologist Rahul Purwar in 2013, ImmunoACT was spun off from the department of bioengineering department of IIT Bombay in 2018. ImmunoACT's NexCAR19 is the first indigenously developed breakthrough cancer CAR-T (chimeric antigen receptor T-cell) therapy approved by India's central drug regulatory agency in October 2023. NexCAR19 was formally launched in India in April 2024 at a price ~90% cheaper than its US and European counterparts like Novartis and Gilead, making it far more affordable for India and low-and-middle income countries, on its potential approval. So far, the therapy has been infused in over 350 patients across 70 hospitals in India. In CAR-T treatment, the patient's immune cells are extracted and through a maze of re-engineering processes infused back to recognize and kill cancer cells, giving a longer remission to patients as compared to the conventional options like immunotherapy or bone marrow transplants. The therapy is used when all other options are CAR-T dose (one-and-done infusion) costs around ₹30 lakh, which was initially priced at ₹42 lakh, and is expected to see a further decline as demand picks ImmunoACT has recently appointed former managing director of Roche India V Simpson Immanuel as its strategic Purwar added, "We needed someone who understands not just the commercial landscape, but also the nuances of innovation, patient access, and global expansion." Earlier this year, Immuneel Therapeutics, backed by leading names like Kiran Mazumdar-Shaw and globally renowned oncologist Siddhartha Mukherjee secured approval for Qartemi, its cell therapy for adult B-cell non-Hodgkin Lymphoma, in India. Companies like Cipla, Dr Reddy's Labs and Bharat Biotech are investing heavily in new CAR-Ts. Globally, CAR-Ts are at the frontiers of a range of cancer treatments, attracting billions of dollars in investments from large drugmakers. The market for such therapies is expected to touch $134 billion by 2034 from around $10 billion at present.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store